Introduction
Since becoming abundant in the atmosphere approximately 2.3 billion years ago as a metabolic byproduct of early life forms, molecular oxygen has been a defining element for life on our planet. Its accumulation in the atmosphere led to development of entirely new organisms -the so-called 'aerobic' organisms. This enormous evolutionary leap was made possible by the unique ability of oxygen to serve as an acceptor of electrons, a feature that enabled the production of energy through a new, markedly more efficient process: oxidative phosphorylation (Balaban et al., 2005; Storz, 2006) . The unprecedented benefits afforded by oxygen, however, came at high price, owing to the toxicity of this element. The original accumulation of oxygen on Earth caused extinction of most existing life forms, unprepared for the new challenge. Surviving life was forced to either escape from oxygen or evolve defense mechanisms to cope with its toxicity. Remarkably, not only were early organisms capable of successfully developing such mechanisms, they also learned to control and exploit the reactivity of this element and its derivatives -the so-called reactive oxygen species (ROS) -for intracellular signal transduction. Indeed, ROS now appear to be involved as key second messengers in numerous signaling pathways, eliciting a diverse array of biological responses ranging from transcriptional regulation, differentiation and proliferation to oncogenic transformation (Curtin et al., 2002; Martindale and Holbrook, 2002; Storz, 2006) . Nevertheless, ROS seemingly play an especially important role in pathways leading to the activation of programmed cell death (PCD) (Curtin et al., 2002; Matsuzawa and Ichijo, 2005) .
One signaling pathway that engages in a unique crosstalk with ROS is that mediating activation of nuclear factor-kappa B (NF-kB) family transcription factors (Sakon et al., 2003; Pham et al., 2004; Kamata et al., 2005; Karin, 2006; Papa et al., 2006) . These transcription factors are master coordinators of immunity, inflammation, differentiation and cell survival (Kucharczak et al., 2003; Hayden and Ghosh, 2004; Claudio et al., 2006) . Soon after the initial discovery of NF-kB, several studies implicated ROS as central effectors for activation of this factor by an array of triggers (Schreck et al., 1991; reviewed in Baeuerle and Henkel, 1994; Flohe et al., 1997; Gloire et al., 2006) . These early observations were followed by a decade devoted primarily to the discovery of the essential molecules and biochemical events involved in the many signaling cascades controlling NF-kB activity and, during which time, ROS were somewhat marginalized from the main fields of NF-kB and signal transduction. However, in recent years ROS have regained center stage in these fields. Molecular mechanisms for ROS-mediated control of NF-kB activity are now beginning to be delineated, at least to some extent, and new studies have uncovered the existence of an additional, unexpected link between ROS and NF-kB -one whereby NF-kB is a key negative regulator of oxidant activity induced in response to stress and cytokines. This negative control that NF-kB exerts on ROS formation appears to be especially crucial for the suppression of PCD induced by the proinflammatory cytokine tumor necrosis factor (TNF)a and perhaps other stimuli (Sakon et al., 2003; Pham et al., 2004; Kamata et al., 2005; Papa et al., 2006) . In addition to antagonism of TNFa-induced PCD, the prosurvival action of NF-kB is essential for B and T lymphopoiesis, bone morphogenesis and pathogenesis of widespread human diseases, ranging from cancer and chronic inflammation to vascular and metabolic disorders (Kucharczak et al., 2003; Greten and Karin, 2004; Kumar et al., 2004; Bottero et al., 2006; Courtois and Smahi, 2006; Karin, 2006; Kim et al., 2006; Papa et al., 2006) . Thus, ROS appear to be at an obligatory crossroads of opposing pathways for life and death elicited by the engagement of TNF receptors (TNF-Rs) and, most likely, other triggers. This has sparked renewed interest in gaining a further understanding of the biological activities and regulation of these elusive molecules and their dynamic interplay with NF-kB.
The different aspects of the regulation and functions of NF-kB-family transcription factors and their role in control of PCD are the subject of other articles in this issue (Dutta et al., 2006; Gilmore, 2006; Perkins, 2006; Scheidereit, 2006) and of excellent reviews previously published elsewhere (Gerondakis and Strasser, 2003; Kucharczak et al., 2003; Hayden and Ghosh, 2004; Bottero et al., 2006; Claudio et al., 2006; Courtois and Smahi, 2006; Karin, 2006; Kim et al., 2006; Mattson and Meffert, 2006; Perkins and Gilmore, 2006) Here, we focus on recent discoveries that have unveiled how NF-kB and ROS engage in a mutual cross-talk. Specifically, we discuss the status of our current understanding of the basis for involvement of ROS in activation of NF-kB, and the mechanisms underlying the negative control that NF-kB exerts on these species and, ultimately, PCD. We then go on to discuss the significance of this mutual crosstalk to health and disease.
The role of ROS in regulation of NF-jB signaling
The formation of ROS Aerobic life yields most of its energy from oxidative phosphorylation, a process in which oxygen serves as acceptor of electrons (Balaban et al., 2005; Storz, 2006) . Major byproducts of this process, which in eukaryotes takes place in mitochondria, are ROS. Electron leakage from the electron transport chain causes formation of the superoxide radical ( Á O 2 À), a moderately reactive species that can generate hydrogen peroxide (H 2 O 2 ), which in turn can produce highly reactive hydroxyl radicals ( Á OH), especially in the presence of transition metals such as iron (Curtin et al., 2002; Balaban et al., 2005; Storz, 2006) . Extra-mitochondrial sources of ROS also exist, including peroxisomes, the endoplasmic reticulum (ER), the plasma membrane and the cytosol, where these species are formed through the action of cytochrome P450, xanthine and nicotinamide adenine dinucleotide phosphate (reduced form) (NADPH) oxidases and other enzymes, including those participating in arachidonic acid metabolism such as lipoxygenases (LOXs) and cyclooxygenases (COXs) (Curtin et al., 2002; Lambeth, 2004; Victor et al., 2004; Balaban et al., 2005; Storz, 2006) .
Owing to their high reactivity, ROS represent a serious hazard for the cell, as they can oxidize macromolecules, thus damaging proteins, lipids and DNA (Curtin et al., 2002; Balaban et al., 2005; Storz, 2006) . To cope with these harmful effects of ROS, aerobic cells evolved powerful systems aimed at preventing accumulation of these species, including antioxidant enzymes such as superoxide dismutases (SODs), catalases, glutathione peroxidases (GPx) and peroxiredoxin, and non-enzymatic systems such as vitamins C and E, reduced glutathione (GSH) and thioredoxin (Trx) (Curtin et al., 2002; Balaban et al., 2005; Storz, 2006) . The development of these safeguard systems was key for enabling cells to control and later exploit the reactivity of ROS for signal transduction. ROS are, in fact, implicated as second messengers in an array of biological responses (Thannickal and Fanburg, 2000; Sauer et al., 2001; Curtin et al., 2002; Martindale and Holbrook, 2002; Balaban et al., 2005) ; most often, however, an elevation of their activity is associated with the induction of PCD (Curtin et al., 2002; Martindale and Holbrook, 2002; Papa et al., 2006) . Indeed, many death-inducing stimuli were recently shown to have the ability to activate the signaling molecule, p66Shc, which upon activation prompts the production of ROS in mitochondria, causing oxidation of cytochrome c and ultimately cell death (Giorgio et al., 2005) .
The NF-kB pathway A family of factors whose regulation and function appears to be intimately linked to ROS is the NF-kB family of transcription factors (Bowie and O'Neill, 2000; Gloire et al., 2006; Nakano et al., 2006) . These transcription factors are central, coordinating regulators of immunity, inflammation, development, growth and cell survival. In mammals, the NF-kB family consists of NF-kB1 (p50/p105), NF-kB2 (p52/p100), RelA (p65), c-Rel and RelB, all characterized by the presence of the Rel homology domain (RHD), which mediates DNA binding, dimerization between members of this family and association of NF-kB dimers with regulatory proteins of the IkB group (Hayden and Ghosh, 2004; Gilmore, 2006) . Normally, NF-kB complexes lie latent in the cytosol, bound to IkBs. A wide range of stimuli, including cytokines and stress, are capable of activating NF-kB from these inactive cytosolic pools -a process that typically involves sequential phosphorylation and proteolysis of IkB inhibitors by the IkB kinase (IKK) complex (consisting of the subunits IKKa, IKKb and NEMO) and the ubiquitin/proteasome system, respectively (Hayden and Ghosh, 2004; Gilmore, 2006; Scheidereit, 2006) . Two main pathways for NF-kB activation have been reported so far (Hayden and Ghosh, 2004; Gilmore, 2006) . The canonical pathwaytriggered in response to proinflammatory cytokines, microbial products and stress -which depends on IKKb and leads primarily to activation of p50/RelA and p50/ c-Rel dimers. The non-canonical pathway -engaged by various members of the TNF-R family such as lymphotoxin (LT)b and BAFF receptors -which depends solely on IKKa and results in activation of p52/RelB complexes (Hayden and Ghosh, 2004; Claudio et al., 2006) . Other routes of activation, however, such as that involving phosphorylation of the p50 precursor, p105, by the kinase Tpl2, followed by proteolytic processing, also exist (Belich et al., 1999) . Upon destruction of the IkB inhibitors, NF-kB dimers then enter the nucleus to regulate expression of target genes, among which are those encoding numerous cytokines, adhesion molecules, growth factors, immune receptors and prosurvival proteins, thereby coordinating immune and inflammatory reactions, cell growth, differentiation and survival (Pahl, 1999; Kucharczak et al., 2003; Hayden and Ghosh, 2004; www.nf-kb.org) .
Early studies implicating ROS in activation of NF-kB: A historical perspective An early problem in the field of NF-kB was to account for the ability of the transcription factor to respond to an unusually vast array of activating stimuli. A model that rapidly gained broad support and appeared to explain this promiscuity of NF-kB was proposed early on by Baeuerle and colleagues. This model postulated that all NF-kB-activating stimuli shared the ability to induce H 2 O 2 , and that this molecule then acted as a general second messenger for signal-induced NF-kB activation (Schreck et al., 1991; Baeuerle and Henkel, 1994; Flohe et al., 1997; Michiels et al., 2002) . Several lines of evidence seemed to argue in favor of this model. Treatment with antioxidant agents such as N-acetyl-L-cysteine (NAC) and pyrrolidine dithiocarbamate (PDTC) blocked activation of NF-kB by an array of stimuli, including TNFa, IL-1b, phorbol 12-myristate 13-acetate (PMA), lipopolysaccharide (LPS), doublestranded (ds)RNA, cycloheximide and H 2 O 2 , in a wide range of cell types (Schreck et al., 1991; Bowie and O'Neill, 2000; Schoonbroodt and Piette, 2000; Gloire et al., 2006) . These findings were corroborated by the use of other antioxidant compounds, such as vitamin C, vitamin E derivatives, a-lipoic acid, butylated hydroxyanisole (BHA) and the iron chelator, deferoxamine (DFO) (Bowie and O'Neill, 2000; Garg and Aggarwal, 2002) . More importantly, the induction of NF-kB was also abrogated by the overexpression of ROS-scavenging enzymes such as catalase, GPxs, thioredoxin peroxidase and Mn 2 þ superoxide dismutase (Mn-SOD) (Bowie and O'Neill, 2000; Gloire et al., 2006) exhibiting highly specific antioxidant activity (Manna et al., 1998; Bowie and O'Neill, 2000) . Further, most NF-kB-activating agents were initially found to induce the formation of ROS (Schreck et al., 1992a; Schmidt et al., 1995; Bowie and O'Neill, 2000; Gloire et al., 2006) , and frank exposure to H 2 O 2 or other oxidants was shown to trigger nuclear translocation of NF-kB in certain cells (Bowie and O'Neill, 2000; Gloire et al., 2006) .
Numerous studies, however, later challenged this view (Brennan and O'Neill, 1995; Li and Karin, 1999; Bowie and O'Neill, 2000; Gloire et al., 2006) . It was shown that H 2 O 2 is unable to induce NF-kB in certain cells, and that the effects of antioxidant agents on activation of NF-kB are dependent upon stimulus and cell type (Bonizzi et al., 1996; Bowie et al., 1997; Li and Karin, 1999; Bowie and O'Neill, 2000; Schoonbroodt and Piette, 2000) . For example, antioxidants were shown to inhibit NF-kB induction by cytokines in some cells (i.e., lymphoid and monocytic cells), but not in others (i.e., epithelial cells) (Bonizzi et al., 1996; Gloire et al., 2006) . Other studies later confirmed that induction of NF-kB by these cytokines is refractory to the suppressive effects of NAC, PDTC and other antioxidants in various tissues (Moynagh et al., 1994; Brennan and O'Neill, 1995; Bonizzi et al., 1996; Bowie et al., 1997; Shrivastava and Aggarwal, 1999; Bowie and O'Neill, 2000; Garg and Aggarwal, 2002; Hayakawa et al., 2003) . Of interest, in some systems, the susceptibility of NF-kB activation to PDTC-mediated inhibition has been associated with the transformation status of the cell (Bowie et al., 1997; Bowie and O'Neill, 2000) . Together, these studies indicate that ROS formation is not a mandatory requirement for activation of NF-kB, and suggest a model whereby participation of this formation in NF-kB signaling depends upon a tissue-and stimulusspecific elements.
Notably, recent reports have even cautioned against a straightforward interpretation of previous studies using standard antioxidant agents, which serves as an invitation to revisit much of the previous literature on this topic. It was found that commonly used compounds such as NAC and PDTC can attenuate NF-kB activation through mechanisms that are independent of their antioxidant functions (Brennan and O'Neill, 1996; Hayakawa et al., 2003) . One study reported that the ability of NAC to blunt TNFa-induced NF-kB activation in various systems is due to interference with binding of TNFa to TNF R1, rather than to the disposal of ROS (Hayakawa et al., 2003) . This study also reported that PDTC blocks IkB-ubiquitin ligase activity -required for signal-induced proteolysis of IkBa (Hayden and Ghosh, 2004) -not only in vivo but also in a cell-free system in which ROS production does not occur (Hayakawa et al., 2003) . In either system, PDTC exhibited prooxidant (rather than antioxidant) activity and it was by means of this activity that it blocked activation of NF-kB (Nobel et al., 1995; Brennan and O'Neill, 1996; Bowie and O'Neill, 2000) . Indeed, several other studies seem to support the view that in some contexts ROS may behave as antagonists, rather than agonists, of NF-kB activity (Shrivastava and Aggarwal, 1999; Schoonbroodt and Piette, 2000; Garg and Aggarwal, 2002; Haddad, 2002; Gloire et al., 2006) (see below).
Studies with ROS-scavenging enzymes have also been unable to clarify these issues. Whereas in one study, overexpression of Mn-SOD led to the inhibition of multiple signaling pathways induced downstream of TNF-Rs, including the NF-kB pathway (Manna et al., 1998) ; in another study, Mn-SOD overexpression in the same cells (i.e., MCF-7 cells) yielded a potentiation of TNFa-elicited NF-kB activation (Schmidt et al., 1995; Bowie and O'Neill, 2000) -an effect originally argued to support a role for H 2 O 2 (a product of dismutase activity) in NF-kB activation (Schreck et al., 1992a, b; Schmidt et al., 1995; Bowie and O'Neill, 2000; JanssenHeininger et al., 2000; Haddad, 2002) . Overexpression of catalase, which disposes instead of H 2 O 2 , also produced confounding results, as catalase was shown to blunt TNFa-mediated induction of NF-kB in some cells (Schmidt et al., 1995) , but not in others (Suzuki et al., 1995) .
Other lines of evidence appear to argue against a universal role for ROS in NF-kB signaling. It was noted, for instance, that activation of NF-kB by exposure to H 2 O 2 proceeds slowly (generally taking hours), whereas that by other stimuli such as cytokines is often detected within a few minutes -before any measurable elevation of ROS levels by these stimuli (Bonizzi et al., 1996; Li and Karin, 1999; Bowie and O'Neill, 2000; Gloire et al., 2006) . Further, it was reported that not all inducers of NF-kB have the ability to also trigger ROS formation (Royall et al., 1992; O'Donnell et al., 1995; Bonizzi et al., 1996; Bowie et al., 1997; Bowie and O'Neill, 2000; Gloire et al., 2006) . Hence, whereas ROS may play a physiological role in the pathways leading to activation of NF-kB elicited by certain stimuli, the biological significance of ROS in other NF-kB activation pathways has yet to be established. The development of new, more sophisticated methods for specific and sensitive detection of ROS will undoubtedly help clarify these issues. A major goal is the identification of the precise molecular events that are controlled by ROS in the various pathways for NF-kB activation (see below).
Mechanisms for ROS-mediated activation of NF-kB signaling In bacteria and yeast, it is clear that oxidative stress directly controls the redox state of specific cysteine residues that control the activity of transcription factors that regulate genes for the antioxidant response (Lee et al., 2004; Wood et al., 2004) . Unfortunately, the existing literature offers little mechanistic insight into how intracellular ROS levels might regulate NF-kB signaling. Indeed, although there is now detailed knowledge of the essential biochemical events governing many of the major pathways leading to NF-kB activation, such as those initiated by TNF-R1, IL-1bR and Toll receptors (Hayden and Ghosh, 2004; O'Neill, 2006) , the bases for redox-mediated control of these pathways have remained elusive (Bowie and O'Neill, 2000; Gloire et al., 2006) . Recent studies, however, may provide some clues as to some of these bases. One study reported that antioxidant treatment of HeLa cells blocks TNFa-induced proteolysis, but not phosphorylation of IkBa (Li and Karin, 1999) , suggesting that the ROSregulated step in cytokine-elicited NF-kB signaling lies immediately downstream of activation of IKK, possibly at the levels of IkBa-ubiquitin ligase activity or recognition of phospho-IkBa (Hayden and Ghosh, 2004) . Other studies have confirmed these inhibitory effects of antioxidant compounds and overexpressed peroxidases on IkBa degradation induced by various stimuli, including TNFa, PMA and LPS (Manna et al., 1998; Li and Karin, 1999; Gloire et al., 2006) , which would explain the broad spectrum of activity of certain ROS scavengers.
Some studies, however, appear to disagree with this model. In certain systems, both ROS-scavenging enzymes and antioxidant agents were, in fact, found to also prevent IkBa phosphorylation triggered by cytokines, microbial products or ionizing radiation, suggesting that the ROS-sensitive step in the NF-kB activation pathways induced by these stimuli lies either at the level or upstream of the IKK complex (Traenckner et al., 1994; Kretz-Remy et al., 1996; Gloire et al., 2006) . Experimental evidence for a direct, redoxmediated control of the activity of the IKK complex remains scarce, and the possible mechanism(s) for such control is unclear. It was proposed, however, that oxidation of a critical cysteine residue in the activation loop of IKKa and IKKb (Hayden and Ghosh, 2004) , Cys-179, may stabilize the conformation and/or interaction of these kinases with each other or with other components of the signalosome (Schoonbroodt and Piette, 2000; Michiels et al., 2002; Gloire et al., 2006) . An alternative hypothesis is that upstream, IKKactivating signaling molecules, such as NF-kB-Inducing Kinase (NIK), may be maintained in a non-functional state by an ROS-inhibitable regulator such as Trx (Jin et al., 1997; Bowie and O'Neill, 2000; JanssenHeininger et al., 2000; Schoonbroodt and Piette, 2000; Gloire et al., 2006) . These models await, nevertheless, experimental validation.
Mechanisms for ROS-mediated inhibition of NF-kB activity Accumulating evidence suggests that, although in limited doses, endogenous ROS may play an activating role in NF-kB signaling; above a certain threshold, they may actually negatively impact upon this signaling (Marshall et al., 2000; Michiels et al., 2002) . The basis for this inhibitory effect of ROS on NF-kB activity is now beginning to be unravelled. High levels of oxidized GSH were found to hinder activity of ubiquitinconjugating enzymes, and accordingly, block proteolysis of IkBa following treatment with H 2 O 2 (Obin et al., 1998; Jaspers et al., 2001) . Further, comparative analysis between the structure of the kinase domains of IKKs and related kinases indicated that, in contrast to what was suggested in other reports (discussed above), oxidation of Cys-179 in either IKKa or IKKb would lead to the inhibition, rather than activation, of kinase activity (Chen and Shi, 2002; Michiels et al., 2002; Gloire et al., 2006) . This residue is oxidized, for instance, upon treatment with arsenite (Kapahi et al., 2000) , and this oxidation has been implicated in ROS-mediated inactivation of IKKb function in alveolar epithelial cells (Korn et al., 2001; Gloire et al., 2006) . The physiological relevance of these findings has also yet to be established.
Another mechanism by which ROS may negatively regulate NF-kB signaling is through direct interference with the DNA-binding activity of NF-kB dimers, following their translocation from cytosolic pools. It is a believed fact that, once in the nucleus, NF-kB has to be kept in a reduced state in order to bind to DNA, as shown by the observations that reducing agents such as dithiothreitol and mercaptoethanol can enhance NF-kB DNA binding, whereas oxidizing agents such as diamides can inhibit it (Molitor et al., 1991; Toledano and Leonard, 1991; Bowie and O'Neill, 2000) . Structural studies suggest that these antagonistic effects of ROS are primarily mediated through oxidation of a conserved, redox-sensitive cysteine residue, Cys-62, located in a region of the RHD of p50 that directly contacts DNA (Matthews et al., 1992; Haddad, 2002; Michiels et al., 2002; Nishi et al., 2002; Brigelius-Flohe et al., 2004) . This residue is seemingly subject to redoxmediated control by Trx (Matthews et al., 1992) , a ubiquitous thiol-containing factor that participates in ROS homeostasis and can stimulate the DNA-binding activity of NF-kB (Schoonbroodt and Piette, 2000; Haddad, 2002) . Transient overexpression of Trx increases NF-kB transcriptional activity in luciferase reporter assays (Matthews et al., 1992; Haddad, 2002) . Other reducing agents, such as glutaredoxin, have been proposed to have similar stimulatory effects on NF-kB (Haddad, 2002) . Interestingly, Trx was found to form a stable interaction with the aforementioned DNA-binding loop of p50 (Qin et al., 1995) , prompting reduction Cys-62 in a specific manner (Hayashi et al., 1993; Jin et al., 1997; Hirota et al., 2001; Haddad, 2002) . Hence, it is plausible that the redox-dependent regulation of NF-kB signaling is compartmentalized and subject to a two-step regulatory process ( Figure 1 ): in the cytosol, IkBa degradation and NF-kB activation depend on oxidizing conditions (Hirota et al., 1999; Martindale and Holbrook, 2002; Kabe et al., 2005) ; whereas in the nucleus, DNA binding and transcriptional activity of NF-kB dimers require the presence of a reducing environment, created in part through the action of Trx (Hirota et al., 1999; Haddad, 2002; Martindale and Holbrook, 2002; Kabe et al., 2005) .
Mechanisms for direct activation of NF-kB by ROS
The mechanisms by which exogenous oxidants activate NF-kB seem to differ from those utilized by cytokines or other stress stimuli (Bowie and O'Neill, 2000; Gloire et al., 2006) . In murine T cells, frank exposure to H 2 O 2 induces NF-kB through a pathway that does not appear to involve either the phosphorylation of IkBa at the canonical Ser-32/Ser-36 sites or the activity of IKKs, but instead depends on phosphorylation of Tyr-42 and of Thr and Ser residues within the C-terminal, proline, glutamate, serine, and threonine-(PEST) rich region of IkBa and the subsequent degradation of IkBa by means of calpain proteases (Bowie and O'Neill, 2000; Schoonbroodt and Piette, 2000; Gloire et al., 2006) . This unconventional pathway of NF-kB activation resembles those elicited by hypoxia/ reoxygenation or the phosphatase inhibitor, pervanadate, as these NF-kB activation pathways also depend on phosphorylation of Tyr-42 in IkBa (Bowie and O'Neill, 2000; Gloire et al., 2006) . Some important differences between these pathways, however, are worth noticing. For instance, unlike what is seen with H 2 O 2 , dissociation of NF-kB from Tyr-42-phosphorylated IkBa during hypoxia-reoxygenation appears to occur in the absence of a proteolytic event (Imbert et al., 1996; Beraud et al., 1999; Bowie and O'Neill, 2000; Schoonbroodt and Piette, 2000; Gloire et al., 2006) . Likewise, with pervanadate, IkBa degradation relies on the ubiquitin/proteasome system, rather than on calpains (Mukhopadhyay et al., 2000; Schoonbroodt and Piette, 2000; Gloire et al., 2006) .
Which specific H 2 O 2 -inducible, protein tyrosine kinase(s) (PTKs) are responsible for phosphorylating IkBa on Tyr-42 is presently unclear (Schoonbroodt and Piette, 2000; Gloire et al., 2006) . In certain cells, however, such as Jurkat T cells, Tyr-42 phosphorylation of IkBa appears to depend on p56
Lck and ZAP-70 (Livolsi et al., 2001) . Of interest, in T lymphocytes, both oxidative stress and pervanadate cause an overall increase in tyrosine phosphorylation of cellular polypeptides, thereby mimicking the effects of the triggering of T-cell receptor (Schieven et al., 1994; Griffith et al., 1998) -an action possibly owed to the combined activation of PTKs, such as Src and ZAP-70, and inactivation of protein tyrosine phosphatases (Schoonbroodt and Piette, 2000; Martindale and Holbrook, 2002; Gloire et al., 2006) . In others systems, H 2 O 2 -induced phosphorylation of IkBa has been shown to involve phosphatidylinositol 3-kinase (PI3K) (Beraud et al., 1999) , which can stably interact with Tyr-42-phosphorylated IkBa through the PI3K regulatory subunit p85 (Beraud et al., 1999) and PTKs such as caseine kinase II (Haddad, 2002; Gloire et al., 2006) . Oxidants may also induce activity of pp90 rsk (Abe et al., 2000) , as well as NIK autophosphorylation, events that are both capable of promoting activation of NF-kB (Ghoda et al., 1997; Schoonbroodt and Piette, 2000; Zhang et al., 2001; Gloire et al., 2006) . Whether H 2 O 2 also affects IKK activity directly, however, remains unclear (discussed above).
The NF-jB-mediated control of ROS activity
The prosurvival action of NF-kB Recent studies have shown that ROS activity is subject to negative feedback regulation by NF-kB, and that this negative regulation of ROS is a key means through which NF-kB counters PCD that occurs downstream of activation of TNF-Rs. The prosurvival activity of NF-kB also plays a key role in a wide range of other biological processes, including maturation of B and T lymphocytes (Hayden and Ghosh, 2004; Bottero et al., 2006; Claudio et al., 2006) , innate and adaptive immunity (Weil and Israe¨l, 2006) , bone morphogenesis epidermal homeostasis, hair follicle development, and neuronal development and function (Kucharczak et al., 2003; Mattson and Meffert, 2006) . When deregulated, NF-kB-mediated suppression of PCD also participates in the pathogenesis of widespread human diseases, including various cancers -where it promotes transformation, tumor progression and resistance to anticancer therapy (Brasseres and Baldwin, 2006; Dutta et al., 2006 ; see also Kucharczak et al., 2003; Karin, 2006; Kim et al., 2006) -chronic inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), various inherited conditions, and metabolic and vascular disorders such as type-II diabetes and atherosclerosis (Kucharczak et al., 2003; Kumar et al., 2004; Courtois and Smahi, 2006; Perkins and Gilmore, 2006) . As discussed below, it is plausible that the pathogenetic role that NF-kB plays in these diseases is owed, at least in part, to an inappropriate control of ROS activity.
The TNF-R1 paradigm
The basis for the restraint that NF-kB exerts on ROS activity in a control of PCD is best understood in the case of TNF-R1, the prototypic example of a so-called 'death receptor' (DR) (Aggarwal, 2003; Wajant et al., 2003) . TNF-R1 is the primary receptor for TNFa, a pleiotropic cytokine that plays a key role in governing inflammation, immunity, differentiation, cell growth and PCD (Aggarwal, 2003; Wajant et al., 2003) . In fact, the prosurvival activity of NF-kB was originally unveiled in the context of the response of engagement of TNF-R1 by TNFa. That is, one of the first direct evidences of a prosurvival activity for NF-kB came from the observation that targeted deletion of rela in mice causes embryonic lethality owing to massive apoptosis in the liver (Beg et al., 1995) . Notably, it was later shown that both liver damage and embryonic lethality in rela À/À mice can be reversed by compound ablation of TNF-R1 (Doi et al., 1999; Alcamo et al., 2001) . Subsequent studies broadened the spectrum of action of the protective function of NF-kB to the biological responses to stimulation of several other members of the TNF-R family such as BAFF-R and RANK -controlling B lymphopoiesis and osteoclastogenesis, respectively, through mechanisms that depend on NF-kB -as well as of DRs in this family, such as Fas (CD95) (Aggarwal, 2003; Kucharczak et al., 2003; Bottero et al., 2006; Claudio et al., 2006) .
Conversely, signaling through TNF-R1 also has the ability of triggering PCD (Wajant et al., 2003) . Despite this well-established ability to kill cells, however, engagement of this receptor by TNFa normally does not result in cell death, unless NF-kB activation or new RNA/ protein synthesis is blocked (Figure 1) (Kucharczak et al., 2003; Wajant et al., 2003; Papa et al., 2006) . Interestingly, these latter conditions can at times occur naturally, as for instance, when NF-kB-mediated control of gene expression is impaired by either viral or parasitic infection or genotoxic stress (Papa et al., 2006) . The bases for these opposing activities of TNF-R1 have recently been clarified. Stimulation of TNF-R1 and other DRs, such as DR3 and DR6, can promote the formation of complex I, consisting of the signaling molecules TNFR1-associated death-domain protein (TRADD), TNF-R-associated factor 2 (TRAF2) or TRAF5, and receptor-interacting protein 1 (RIP1). This complex then leads to activation of NF-kB, which sustains cell survival (Micheau and Tschopp, 2003; Wajant et al., 2003; Schneider-Brachert et al., 2004; Papa et al., 2006) . Upon dissociation from the plasma membrane, however, TRADD and RIP1 associate instead with Fas-associated death domain (FADD), which in turn binds to and activates procaspase-8 and -10, thereby forming complex II, which triggers cell death (Micheau and Tschopp, 2003; Schneider-Brachert et al., 2004; Papa et al., 2006) .
TNF-R1-induced pathways of PCD: necrosis and apoptosis
Engagement of TNF-R1 by TNFa can elicit at least two, distinct pathways of PCD: the apoptotic pathway and the necrotic pathway (Ja¨a¨ttela¨and Tschopp, 2003) . These distinct forms of PCD are usually defined through morphological criteria (Leist and Ja¨a¨ttela¨, 2001 ; Ja¨a¨ttelaä nd Tschopp, 2003; Edinger and Thompson, 2004) , with apoptotic cells being typically characterized by picnosis, chromatin condensation, cytoplasmic shrinkage and plasma membrane blebbing, and necrotic cells exhibiting organelle swelling and disintegration, nuclear degradation, and disruption of the plasma membrane. With TNF-R1, these two pathways appear to diverge immediately downstream of TRADD, with FADD/ caspase-8 signaling to apoptosis and RIP1 signaling to necrosis (Leist and Ja¨a¨ttela¨, 2001; Ja¨a¨ttela¨and Tschopp, 2003) .
The central event in apoptosis is the activation of caspase proteases and this and other essential biochemical steps in this pathway have been delineated in detail (Wajant et al., 2003; Danial and Korsmeyer, 2004) . In contrast, the molecular events involved in signaling to necrosis remain poorly understood. It is clear, however, that the induction of necrosis does not require caspase activity, as this pathway can even be potentiated by an inhibition of these enzymes (Leist and Ja¨a¨ttela¨, 2001; Ja¨a¨ttela¨and Tschopp, 2003; Edinger and Thompson, 2004) . There are also indications that mitochondrial factors such as apoptosis-inducing factor, the serine protease Omi, and lysosomal proteases of the cathepsin group (Ja¨a¨ttela¨and Tschopp, 2003; SchneiderBrachert et al., 2004) , as well as ROS may be important participants in the necrosis pathway elicited by TNF-R1 (Leist and Ja¨a¨ttela¨, 2001; Ja¨a¨ttela¨and Tschopp, 2003) .
The elements controlling the choice between necrosis or apoptosis are also poorly understood (Edinger and Thompson, 2004 ; see also below). A physiologically relevant consequence of making this choice, however, at least in vivo, is that whereas necrotic cells are a trigger for inflammation, apoptotic cells are potent suppressors of both immune and inflammatory responses (Ja¨a¨ttelaä nd Tschopp, 2003; Edinger and Thompson, 2004) . Nevertheless, regardless of whether stimulation of TNF-R1 is poised to trigger necrosis or apoptosis, activation of NF-kB effectively counters PCD signaling downstream of this receptor.
NF-kB-mediated suppression of PCD involves the control of ROS Recent studies from several laboratories indicate that the protective activity of NF-kB against TNF-R-elicited cytotoxicity involves a control of the accumulation of ROS induced by these receptors (Figures 1 and 2 ) (Sakon et al., 2003; Pham et al., 2004; Kamata et al., 2005) . Indeed, ROS are emerging as key second messengers in TNF-R1-induced death signaling (Leist and Ja¨a¨ttela¨, 2001; Ja¨a¨ttela¨and Tschopp, 2003; Sakon et al., 2003; Wajant et al., 2003; Pham et al., 2004; Ventura et al., 2004; Kamata et al., 2005; Matsuzawa and Ichijo, 2005; Karin, 2006; Papa et al., 2006) . Exposure to TNFa was shown to elicit an aberrant elevation of ROS in NF-kB-deficient cells. Conversely, wild-type cells are capable of maintaining redox homeostasis throughout this exposure to TNFa (Sakon et al., 2003; Pham et al., 2004; Kamata et al., 2005) , indicating that restraint of ROS elevation induced downstream of TNF-Rs represents a physiological function of NF-kB (Sakon et al., 2003; Pham et al., 2004; Kamata et al., 2005) . Remarkably, treatment with antioxidant compounds such as NAC, PDTC or BHA virtually abolished TNFa-inflicted killing in NF-kB null cells (Sakon et al., 2003; Pham et al., 2004; Kamata et al., Reactive oxygen species and NF-jB C Bubici et al 2005). Hence, the suppression of TNFa-induced ROS formation is also a key protective mechanism that is mediated by NF-kB (Figure 1 ) (Sakon et al., 2003; Pham et al., 2004; Ventura et al., 2004; Kamata et al., 2005; Papa et al., 2006) . Notably, ROS appear to play a critical role also in PCD signaling initiated by several other triggers, including ionizing radiation, ceramide and chemotherapeutic drugs, and indeed, direct exposure to oxidants suffice alone to induce PCD (Curtin et al., 2002; Martindale and Holbrook, 2002; Matsuzawa and Ichijo, 2005) . Thus, the biological relevance of the NF-kBmediated control of ROS activity may extend to the response to other stimuli, such as stress stimuli. Indeed, some studies support a role for the antioxidant function of NF-kB in cytoprotection against arsenic-and oxidative stress-induced killing (Mattson et al., 1997; Chen et al., 2003; Zhang and Chen, 2004; Nakano et al., 2006) .
Mechanisms for ROS-induced PCD: the role of c-Jun-N-terminal kinase
The c-Jun-N-terminal kinase mitogen-activated protein kinase cascade The precise mechanism(s) through which ROS trigger PCD is unclear. It is possible that, in some circumstances, ROS-inflicted cytotoxicity involves an inhibition of NF-kB (discussed above). It is becoming increasingly clear, however, that in many systems, this cytotoxicity is mediated in part by activation of the c-Jun-N-terminal kinase (JNK) cascade (Figure 1 ) (Pham et al., 2004; Kamata et al., 2005; Matsuzawa and Ichijo, 2005; Papa et al., 2006) , which is one of the major mitogen-activated protein kinase (MAPK) cascades found in mammalian cells (Davis, 2000; Karin and Gallagher, 2005) . Like other MAPK pathways, such as the p38 and the extracellular-regulated kinase (ERK) pathways, the JNK pathway transduces signals initiated by an array of stimuli via sequential phosphorylation of distinct kinase modules, ultimately eliciting an appropriate biological response to these stimuli (Davis, 2000; Karin and Gallagher, 2005) . In mammals, the most distal of these modules consists of the kinases JNK1/2/3, which are primarily activated upon exposure to stress or proinflammatory cytokines such as TNFa and IL-1b (Davis, 2000; Karin and Gallagher, 2005) . Activation of JNK by these triggers has been reported to have different biological outcomes. By and large, however, this activation has been linked to induction of PCD (Davis, 2000; Karin and Gallagher, 2005) . This role of JNK in PCD has been best delineated through the use of JNK-deficient animal models. Compound knockout of jnk1 and jnk2 in mouse embryonic fibroblasts (MEFs) prevents mitochondrial release of cytochrome c and apoptosis elicited by various stress stimuli (Tournier et al., 2000) , and thymocytes and peripheral T cells from jnk1 À/À or jnk2 À/À mice are refractory to anti-CD3-induced PCD and activation-induced cell death, respectively (Karin and Gallagher, 2005; Papa et al., 2006) . Additionally, jnk3 À/À neurons exhibit a severe defect in the apoptotic response to excitotoxins (Yang et al., 1997; Davis, 2000) .
Role of JNK in PCD signaling downstream of TNF-Rs
Despite some initial doubts, the JNK cascade is now widely recognized as an essential player in PCD signaling downstream of TNF-Rs (Franzoso et al., 2003; Papa et al., 2006) . The role of JNK in this signaling was clarified recently through the use of JNKand NF-kB-deficient systems. It was shown that suppression of JNK activation by various meansincluding knockout of jnk genes and silencing of the JNK kinase MKK7 -virtually abrogates TNFa-inflicted cytotoxicity in NF-kB-deficient cells (De Smaele et al., 2001; Tang et al., 2001; Deng et al., 2003; Ventura et al., 2004; Kamata et al., 2005; Papa et al., 2006) . Indeed, these studies demonstrate that the targeting of the JNK pathway represents an important means through which NF-kB counters TNFa-induced cytotoxicity. Consistent Notably, caspases have the ability to activate MAPK kinase kinases (MAP3K), such as MEKK1 (Davis, 2000; Karin and Gallagher, 2005) and so, may contribute to the maintenance of sustained induction of JNK by TNFa. Nevertheless, the inhibitory effects of NF-kB on the JNK cascade do not appear to be a secondary consequence of a suppression of caspase activity, because these effects are seemingly unaffected by the presence of caspase blockers such as z-VAD fmk (Papa et al., 2006) . Hence, NF-kB is a bona fide suppressor of sustained JNK signaling, and the control that it exerts on this signaling is crucial for antagonism of TNF-R-induced PCD (De Smaele et al., 2001; Tang et al., 2001; Papa et al., 2006) . Indeed, there is now evidence that the NF-kB-mediated restraint of prolonged JNK signaling is also important for cell survival following exposure to stress stimuli (Chen et al., 2003; Zhang and Chen, 2004) .
The biological relevance of JNK in promoting TNFainduced killing is underscored by in vivo studies. It was shown, for instance, that jnk1 À/À and jnk2 À/À mice are protected against TNF-R-mediated liver damage elicited by systemic administration of concavalin A (ConA) (see below) (Maeda et al., 2003) . There is, however, lingering debate as to whether activation of JNK by TNFa participates primarily in necrosis or apoptosis signaling (Sakon et al., 2003; Ventura et al., 2004; Nakano et al., 2006) .
Mechanisms for ROS-mediated activation of JNK
In various NF-kB-deficient systems, sustained JNK activation by TNFa is abolished by pretreatment of cells with ROS-neutralizing agents such as NAC and BHA (Sakon et al., 2003; Pham et al., 2004; Kamata et al., 2005) . Notably, the acute phase of this activation is instead virtually unaffected by these agents (Sakon et al., 2003; Pham et al., 2004; Kamata et al., 2005) , indicating that the elevation of ROS and sustained (but not acute) JNK activity are part of the same deathinducing mechanism elicited by TNF-Rs (Figures 1  and 2) (Pham et al., 2004; Kamata et al., 2005; Matsuzawa and Ichijo, 2005) . Exactly how ROS promote long-lasting JNK activation downstream of these receptors remains unclear. Recent studies, however, have provided important insights into the underlying mechanisms of this action of ROS on the JNK pathway. Karin and colleagues reported that phosphatases of the MAP kinase phosphatase (MKP) group, such as MKP-1, MKP-3, MKP-5 and MKP-7 that are known to regulate MAPK activities (Davis, 2000; Karin and Gallagher, 2005) , are key targets of ROS during TNFa-induced PCD signaling (Figure 1 ) . They also showed that ROS cause inactivation of MKPs by oxidizing a highly reactive cysteine residue, critical for catalytic function . This ROS-mediated suppression of MKPs is thought to impair downregulation of the JNK cascade following exposure to TNFa, thus prompting sustained activation of this cascade and, ultimately, PCD (Figure 1) Karin, 2006) . Of note, this study was carried out mainly using pharmacological and dominant-negative tools, and so its conclusions await validation through more rigorous genetic means.
There appear to be other mechanisms through which ROS can promote TNFa-induced JNK signaling. A study by Matsuzawa and Ichijo (2005) showed that ROS also prompt induction of ASK1/MEKK5 (Matsuzawa and Ichijo, 2005) , a TRAF2-interacting MAP3K required for prolonged activation of JNK (and p38) downstream of TNF-R1 (Davis, 2000; Matsuzawa and Ichijo, 2005) . These studies included knockout data, as they showed that ask1-deficient MEFs exhibit a severe (albeit incomplete) defect in induction of JNK signaling and PCD following stimulation of TNF-R1 (Matsuzawa and Ichijo, 2005) . Interestingly, as with MKPs , ROS-mediated activation of ASK1 appears to involve the inhibition of Trx. It is plausible, nevertheless, that the effects of ROS on TNFa-induced JNK signaling are also mediated through induction of MAP3Ks other than ASK1, such as MEKK1 (Matsuzawa and Ichijo, 2005) . However, despite the findings that several of these other MAP3Ks, including MEKK1, GCK, GCKR and MLK3, have been implicated in activation of JNK by TNF-Rs (Davis, 2000; Karin and Gallagher, 2005) , their precise role in sustaining this activation remains unknown. Hence, ROS may influence activation of the JNK pathway downstream of TNF-Rs both by inducing MAP3Ks and by inhibiting MKPs. The relative importance of each of these mechanisms for sustained induction of the TNF-R pathway is likely to depend upon tissue and biological context.
Mechanisms for TNF-R-induced, proapoptotic JNK signaling
The precise mechanism(s) by which JNK activation by TNFa promotes PCD remains uncertain. Cytotoxic JNK signaling can involve either transcriptional or posttranscriptional mechanisms. In neurons, for instance, excitotoxin-inflicted apoptosis depends on JNK3-mediated phosphorylation of the transcription factor, c-Jun, and consequent modulation of gene expression by this factor (Yang et al., 1997; Davis, 2000; Karin and Gallagher, 2005) . Conversely, during challenge with stress stimuli or TNFa, the main targets of JNK involved in promoting PCD appear to be already present in the cell (Davis, 2000; Papa et al., 2006) . Recent studies provide some insights into the basis for JNK-mediated PCD downstream of TNF-Rs. One report suggests that activation of JNK by these receptors triggers cell death by promoting proteolytic processing of the 'BH3-only' protein, Bid, into jBid (distinct from the caspase-8-generated product, tBid) (Deng et al., 2003 ; see also Wajant et al., 2003) . jBid then causes mitochondria to induce selective release into cytosol of the apoptogenic factor Smac/Diablo, resulting in activation of caspase-8 and, ultimately, apoptosis (Figure 1) (Deng et al., 2003; Wajant et al., 2003; Danial and Korsmeyer, 2004) . Interestingly, this JNK-jBidSmac/Diablo-caspase-8 pathway appears to provide another, albeit reverse, link -in addition to the classical, caspase-8-tBid-cytochrome c link -between the mitochondrion and the TNF-R1 complex (Wajant et al., 2003) .
A more recent report proposed another mechanism by which JNK activation by TNFa can promote PCD. The study showed that TNFa-induced sustained JNK signaling accelerates turnover of the caspase-8 antagonist, c-FLIP L , through a mechanism that involves activation of the E3 ubiquitin ligase, Itch, by direct JNK-mediated phosphorylation (Wajant et al., 2003; Chang et al., 2006; Karin, 2006) . Itch-dependent proteolysis of c-FLIP L by the proteasome would then cause activation of caspase-8 and, ultimately, cell death via apoptosis (Figure 1) . Several important questions, however, remain unanswered. For instance, exactly how JNK promotes formation of jBid is unknown. It is also unclear what specific contribution each of the aforementioned mechanisms to JNK-mediated PCD makes in various biological contexts. Furthermore, it is likely that there are also Bid-independent means -not contemplated in either one of these models -for JNK-mediated apoptosis signaling downstream of TNF-Rs (see Papa et al., 2006) . Finally, whereas both JNK and ROS are known to participate in TNFa-induced necrosis signaling (Sakon et al., 2003; Ventura et al., 2004; Kamata et al., 2005; Nakano et al., 2006; Papa et al., 2006) , the basis for their participation remains unknown.
The origin of TNFa-induced ROS
The mechanisms by which TNF-Rs elicit ROS formation are not precisely known. Nevertheless, this formation is often assumed to occur in mitochondria (Ja¨a¨ttelaä nd Tschopp, 2003; Kamata et al., 2005; Nakano et al., 2006; Papa et al., 2006) , which is the main source of ROS in eukaryotes (Curtin et al., 2002; Storz, 2006) . Previous studies, however, were unable to differentiate between ROS acting as second messengers in TNF-R-induced signaling and those produced as a result of the oxidative burst that follows mitochondrial outer membrane permeabilization (Ja¨a¨ttela¨and Tschopp, 2003; Sakon et al., 2003; Kamata et al., 2005; Ventura et al., 2004) , an indication that the cell is already committed to die (Wajant et al., 2003) . Indeed, executioner caspase-3 can induce the production of ROS in mitochondria by cleaving components of complex I of the electron transport chain (Ricci et al., 2004) . Thus, whether mitochondrial production of ROS is a cause or a consequence of PCD remains unclear. The observations that TNFa-elicited ROS elevation can be blocked by compound disruption of jnk1 and jnk2 could be a mere reflection of the lack of cell death that results from this double mutation (Ventura et al., 2004) . In further support of a primary extra-mitochondrial origin of TNFa-induced ROS, overexpression of the mitochondrial ROS scavenger, Mn-SOD, affords only modest cytoprotection against TNF-R-mediated killing in NF-kB null cells (Sakon et al., 2003; Pham et al., 2004) .
Indeed, extra-mitochondrial enzymes were previously implicated as potential source of ROS during TNF-R-induced PCD signaling. These include cytosolic phospholipase A2 (cPLA2), ER-associated, NADPH cytochrome P450 reductase and plasma membrane NADPH oxidase (Thannickal and Fanburg, 2000; Sauer et al., 2001; Haddad, 2002; Ja¨a¨ttela¨and Tschopp, 2003; Lambeth, 2004; Victor et al., 2004; Nakano et al., 2006; Papa et al., 2006) . COXs and LOXs were also proposed to play a role in ROS induction downstream of TNF-Rs (and IL-1bR) (Bonizzi et al., 1999; Bowie and O'Neill, 2000; Thannickal and Fanburg, 2000; Victor et al., 2004; Gloire et al., 2006; Nakano et al., 2006) . Thus, it seems likely that multiple mechanisms are responsible for cytokine-elicited ROS production, and that the relative importance of each of these mechanisms differs depending on the tissue. With regard to this, it is worth noting that the ROS involved in activation of NF-kB downstream of IL-1bR in lymphoid and monocytic cells have been proposed to be produced by different enzymatic systems, namely by the 5-LOX and NADPH oxidase systems, respectively (Bonizzi et al., 1999; Bonizzi et al., 2000; Gloire et al., 2006) . Ultimately, for a precise delineation of the mechanisms underlying formation of ROS downstream of TNF-Rs, it will be necessary to develop more specific and sensitive methods for detection of individual reactive species and to determine the precise location of these species within the cell.
TNF-R-induced signaling pathways leading to ROS formation
The upstream pathways leading to ROS formation also remain unknown. Both RIP1 and FADD, however, appear to be required for eliciting ROS formation downstream of TNF-Rs (Ja¨a¨ttela¨and Tschopp, 2003) . Of interest, participation of RIP1 in induction of ROS (and programmed necrosis) depends on its kinase activity, a function not required for its participation in NF-kB activation (Holler et al., 2000; Ja¨a¨ttela¨and Tschopp, 2003) . In certain systems, both RIP1-and TNF-R-triggered elevation of ROS appears to be independent of caspase activity. In fact, in some cases, both this elevation and necrosis signaling are even enhanced by inhibition of caspases (Vercammen et al., 1998; Holler et al., 2000; Ja¨a¨ttela¨and Tschopp, 2003; Liu et al., 2003; Papa et al., 2006 ). Yet, in other systems, caspases appear to be themselves key participants in the DR-induced pathways leading to ROS formation (Leist and Ja¨a¨ttela¨, 2001; Ja¨a¨ttela¨and Tschopp, 2003; Papa et al., 2006) . Thus, ROS accumulation induced downstream of DRs seemingly involves both caspase-dependent and caspase-independent mechanisms (Vercammen et al., 1998; Holler et al., 2000; Cauwels et al., 2003; Vanden Berghe et al., 2003) .
The relationship between ROS and JNK in necrosis and apoptosis signaling
Mutual regulation of ROS and JNK signaling
Most studies now agree that ROS lie upstream of JNK in the TNF-R-induced pathways of PCD (Figure 1 ) (Sakon et al., 2003; Pham et al., 2004; Kamata et al., 2005, Matsuzawa and Ichijo, 2005) , and that attenuation of ROS represents an indirect means through which NF-kB exerts a restraint on the JNK cascade and, ultimately, on PCD (Sakon et al., 2003; Pham et al., 2004; Papa et al., 2006 ). Yet, some data indicate that TNFa-elicited induction of ROS can also occur downstream of JNK activation (Ventura et al., 2004) , suggesting that the causal relationship between ROS and JNK activities in these pathways is actually more complex (Figure 2 ). Compound mutation of jnk1 and jnk2 in NF-kB-deficient MEFs was shown to abrogate ROS accumulation elicited by exposure to TNFa -an accumulation seen instead in the absence of NF-kB in JNK-proficient cells (Ventura et al., 2004) . This led to the conclusion that ROS and JNK activities participate in a mutual amplification mechanism that is ultimately responsible for the triggering of cell death downstream of TNF-Rs (Figure 2 ). Yet, whereas a dynamic relationship between these activities is likely to exist, it should be cautioned that the antioxidant effects of JNK inactivation in this system might be due in part to a suppression of PCD. Indeed, exactly how TNFa-induced JNK might promote ROS formation remains uncertain. It should be noted, though, that activation of cPLA2 and mitochondrial complex III were previously proposed as potential mechanisms for JNK-mediated enhancement of this formation downstream of TNF-Rs (Leist and Ja¨a¨ttela¨, 2001; Garg and Aggarwal, 2002; Ja¨a¨ttela¨and Tschopp, 2003; Ventura et al., 2004; Papa et al., 2006) .
Relative ordering of ROS and JNK activities in necrosis and apoptosis
While promoting apoptosis (Lamb et al., 2003) , suppression of JNK in the aforementioned study protected NF-kB-deficient fibroblasts against TNFainduced necrosis (Ventura et al., 2004) , suggesting that JNK and ROS activities are predominantly involved in induction of necrosis in this system. Other studies confirmed a role for JNK and ROS in TNFa-induced necrosis (Leist and Ja¨a¨ttela¨, 2001; Ja¨a¨ttela¨and Tschopp, 2003; Sakon et al., 2003; Kamata et al., 2005) . Yet, in some NF-kB null systems, TNF-R-elicited JNK and ROS activities have primarily been implicated in induction of apoptosis (De Smaele et al., 2001; Tang et al., 2001; Pham et al., 2004) . Hence, the actual outcome of activation of ROS and JNK signaling may ultimately depend on the biological context and tissue in which these activations occur (Davis, 2000; Papa et al., 2006) . Indeed, an intriguing possibility presented by previous studies is that the relative positioning of ROS with respect to JNK activity dictates which pathway of PCD is ultimately elicited in response to the triggering of TNF-Rs (Sakon et al., 2003; Pham et al., 2004; Ventura et al., 2004; Kamata et al., 2005) . For example, a positioning of JNK signaling upstream of ROS has been linked to the induction of necrosis (Ventura et al., 2004) , whereas the inverse positioning of JNK downstream of ROS has been linked to the induction of apoptosis (Pham et al., 2004; Matsuzawa and Ichijo, 2005) . Regardless of the nature of the death mechanism that is triggered by TNFa, in almost all studies, the net effect of a suppression of JNK or ROS activities is an enhancement of cell survival (De Smaele et al., 2001; Tang et al., 2001; Deng et al., 2003; Sakon et al., 2003; Pham et al., 2004; Ventura et al., 2004; Kamata et al., 2005) , indicating that these activities are essential effectors of TNF-R-induced cytotoxicity, either via necrosis or apoptosis. Notably, irrespective of the specific hierarchy of ROS and JNK signaling and the nature of the PCD mechanism that is triggered by TNFa, it is now clear that both types of PCD responses can be effectively halted by activation of NF-kB (Pham et al., 2004; Ventura et al., 2004; Kamata et al., 2005; Nakano et al., 2006; Papa et al., 2006) .
The mechanisms dictating which form of PCD is ultimately triggered by TNF-Rs are poorly understood. It is likely, however, that the contribution of ROS and JNK activities to apoptosis and necrosis signaling is subject to context-and tissue-specic elements. Furthermore, it is plausible that both qualitative and quantitative aspects of ROS and JNK activities, such as intensity and duration, also play an important role in determining the biological outcome of TNF-R stimulation with regard to cell fate (Fiers et al., 1999; Nakano et al., 2006; Papa et al., 2006) . Finally, another element that is increasingly being recognized as critical in influencing the choice between induction of necrosis and apoptosis is the metabolic state of the cell (Hammerman et al., 2004; Edinger and Thompson, 2004) .
Basis for the NF-jB-mediated targeting of ROS activity

Ferritin heavy chain
The bases for the NF-kB-mediated control of ROS activity are beginning to be elucidated (Figure 1) . By and large, this control appears to involve an induction of target genes (Nakano et al., 2006; Papa et al., 2006) . Using a microarray-based screen, ferritin heavy chain (FHC) was identified as a critical mediator of the antioxidant and antiapoptotic activities of NF-kB downstream of TNF-Rs (Pham et al., 2004) . Together with light chains (FLC), FHC assembles into ferritin complexes -large hetero-polymers that constitute the primary reservoirs of iron in cells (Arosio and Levi, 2002; Torti and Torti, 2002; Hentze et al., 2004) . In eukaryotes, iron is involved in both production of mitochondrial Á O 2 À and Fenton and Haber-Weiss reactions, generating highly reactive Á OH radicals (Arosio and Levi, 2002; Curtin et al., 2002; Torti and Torti, 2002) . Thus, limiting availability of iron, through upregulation of ferritin, is an important means by which ROS levels can be controlled in cells. FHC gene expression is induced by TNFa through a mechanism that depends on NF-kB, is required for antagonism of TNFa-induced cytotoxicity, and upon overexpression, counters apoptosis in NF-kB-deficient cells (Pham et al., 2004) . The protective activity of FHC against TNFainflicted PCD is mediated through sequestration of iron, which prevents the accumulation of ROS and the consequent sustained activation of the JNK cascade (Figure 1 ) (Pham et al., 2004) . The importance of FHC for the NF-kB-mediated restraint of TNF-R-induced JNK signaling and PCD has been validated in FHCdeficient and in vivo systems. That is, silencing of FHC expression in fibroblasts results in persistent activation of JNK by TNFa and increased TNF-R-induced killing (Pham et al., 2004) . Induction of FHC appears also to play a critical role in the control of TNFa-elicited fluctuations in the intracellular labile iron pool (LIP) (Xie et al., 2005) . Remarkably, systemic administration of the iron chelator, DFO, protects mice against TNF-R-mediated lethality and tissue injury (Vulcano et al., 2000) .
Interestingly, a new study suggests that, in addition to blocking apoptosis signaling, FHC halts TNFa-induced programmed necrosis (Xie et al., 2005) . Thus, unlike other NF-kB-activated factors, FHC seems capable of suppressing both pathways of PCD induced downstream of TNF-Rs (Pham et al., 2004 , Xie et al., 2005 . Thus, it is possible that the iron-mediated control of ROS production may even contribute to determining which pathway of PCD is ultimately triggered by TNF-Rs.
Notably, FHC is one of the several acute-phase proteins induced in the liver during a systemic organismal response to stress, injury and microbial infection (Torti and Torti, 2002; Hentze et al., 2004) . This induction of FHC is initiated by TNFa and other proinflammatory cytokines and is an important contributing element of hypoferremia, which is a common occurrence in patients with chronic inflammatory conditions (Torti and Torti, 2002; Hentze et al., 2004) . Of note, this generalized restriction of iron availability might enable NF-kB to limit ROS-mediated damage at distant sites, such as sites of inflammation, where there are elevated, potentially harmful levels of ROS and TNFa (Haddad, 2002; Kumar et al., 2004) . Accumulating evidence suggest that FHC also plays an important role in mediating some of the critical functions of NF-kB in cancer (Benhar et al., 2002; Torti and Torti, 2002 ). An elevation of ROS is often required for malignant transformation, even though it also enhances the propensity of malignant cells to undergo death, both basally and upon treatment with anticancer drugs (Benhar et al., 2002; Curtin et al., 2002; Torti and Torti, 2002) . With tumor progression, however, growth often becomes independent of ROS (Benhar et al., 2002) , which enables certain cancer cells to upregulate FHC expression (Torti and Torti, 2002) . Notably, the protective activity of FHC extends to genotoxic and oxidative stress (Arosio and Levi, 2002; Torti and Torti, 2002) , and in certain human tumors, high FHC levels have been associated with anaplasia, metastatic spread and poor prognosis (Torti and Torti, 2002; Hentze et al., 2004; reviewed in Papa et al., 2006) . Thus, induction of FHC may represent a means by which NF-kB promotes oncogenesis, tumor progression and cancer resistance to anticancer treatments.
Manganese superoxide dismutase
Several laboratories have shown that the antioxidant and protective activities of NF-kB are also mediated in part by upregulation of the ROS-scavenging enzyme Mn-SOD (Figure 1) (Bernard et al., 2001; Delhalle et al., 2002; Kucharczak et al., 2003; Papa et al., 2006) , which catalyses dismutation of Á O 2 À into H 2 O 2 (Curtin et al., 2002) . Mn-SOD is a TNFa-inducible target of NF-kB, and upon ectopic expression, Mn-SOD can blunt TNFainflicted cytotoxicity in certain systems (Figure 1 ) (Bernard et al., 2001; Delhalle et al., 2002; Kucharczak et al., 2003; Pham et al., 2004; Kamata et al., 2005) . Its overall significance to the protective action of NF-kB, however, is still uncertain. This is because in various NF-kB-deficient models overexpressed Mn-SOD affords little or no protection against TNF-R-mediated killing (Sakon et al., 2003; Pham et al., 2004) . This enzyme also scored poorly in a genetic screen for factors capable of protecting rela À/À cells against TNF-induced killing (Pham et al., 2004) . Further, in some cell types, Mn-SOD expression appears to be independent of either TNFa or NF-kB (Pham et al., 2004) , suggesting that in these cell types, it is not involved in the prosurvival effect of NF-kB.
Although Mn-SOD appears to be insufficient for control of ROS formation and PCD downstream of TNF-Rs, it is likely to be an essential element for the antioxidant and protective functions of NF-kB in several other contexts. Indeed, there is suggestive evidence that Mn-SOD might contribute to the prooncogenic action of NF-kB, as for instance in some leukemias (Papa et al., 2006) . For effective control of redox homeostasis, synergism between Mn-SOD and FHC is likely to be crucial. Although upregulation of Mn-SOD promotes conversion of Á O 2 À into H 2 O 2 , FHC-mediated sequestration of iron may promote disposal of H 2 O 2 by peroxidases and catalases (Curtin et al., 2002; Torti and Torti, 2002) . In NF-kB-deficient cells, levels of FHC are normally low (Pham et al., 2004) , and as a result, free iron is available for catalysing
Reactive oxygen species and NF-jB C Bubici et al the Fenton reaction, which reduces H 2 O 2 into highly reactive Á OH radicals (Curtin et al., 2002) . This might account for the inability of overexpressed Mn-SOD by itself to block TNFa-induced PCD in these cells (Delhalle et al., 2002; Sakon et al., 2003; Pham et al., 2004) .
Additional mechanisms for the antioxidant activity of NF-kB There are other mechanisms through which NF-kB might participate in redox homeostasis. NF-kB has been implicated in upregulation of g-glutamyl-cysteine synthetase -the rate-limiting enzyme in GSH synthesis -by proinflammatory cytokines and other stimuli (Griffith et al., 1998; Victor et al., 2004) . Other antioxidant enzymes, such as metallothionein and glutathione S-transferase, have also recently been suggested to be under transcriptional control of NF-kB (Sasazuki et al., 2004) . Interestingly, the NF-kB-mediated restraint of ROS activity might even involve a downregulation of prooxidant factors. Knockout of ikkb or overexpression of dominant-negative IKKb mutants results in increased expression of members of the P450 family, such as cyp1b1, and this increase is associated with an elevation of ROS levels (Chen et al., 2003; Zhang and Chen, 2004; Nakano et al., 2006) . The basis for the effects of NF-kB on cyp1b1 expression has yet to be determined (Zhang and Chen, 2004; Nakano et al., 2006) . Nevertheless, these findings underscore the complexity and multifactorial nature of the mechanism through which NF-kB controls ROS homeostasis, which is likely a key element for effective elimination of ROS.
Direct control of the JNK cascade by NF-kB
In addition to providing a basis for the antioxidant activity of NF-kB, the combined upregulation of the genes encoding FHC and Mn-SOD (and possibly of other genes) establishes a crucial, albeit indirect, link between the NF-kB and JNK pathways (Figure 1 ) (Sakon et al., 2003; Pham et al., 2004) . There are, however, also direct means through which NF-kB restrains the JNK cascade. A subset of NF-kB target genes has been found to encode bona fide inhibitors of this cascade (Papa et al., 2006) . These include the following: a member of the Gadd45 family, Gadd45b/ Myd118; the zinc-finger protein A20 and the caspase inhibitor of the IAP group, XIAP (Figure 1 ) (reviewed in Papa et al., 2006) . Gadd45b can physically interact with and block activity of MKK7 , the dominant JNK kinase induced downstream of TNF-Rs (Davis, 2000; Papa et al., 2006 ). The precise mechanisms by which XIAP and A20 blunt activation of the JNK cascade remain to be determined. Further, genetic evidence for a participation in NF-kB-mediated antagonism of TNFa-induced JNK activation and PCD has been previously obtained for A20 and Gadd45b (Papa et al., 2006) . In contrast, targeted deletion of the xiap gene was found to have no apparent effect on induction of the JNK cascade and PCD downstream of TNF-Rs (Kucharczak et al., 2003) . Thus, the relevance of XIAP to the NF-kB-mediated control of this cascade remains to be established. Hence, NF-kB appears to exert a restraint on TNFaelicited JNK signaling through at least two distinct mechanisms: directly, via induction of Gadd45b, A20 and XIAP; and indirectly, via induction of FHC and Mn-SOD (and likely other factors), which blunt production of ROS (Figure 1) . Most likely, this use of multiple downstream effectors by NF-kB serves to ensure effective inhibition of the JNK pathway. The relevance of each of these effectors to the NF-kBmediated antagonism of JNK signaling and PCD, however, is likely to differ depending upon specific cell type and biological context (Kucharczak et al., 2003; Nakano et al., 2006; Papa et al., 2006) . This adaptable gene program may enable an organism to precisely orchestrate its prosurvival response based upon specific challenges and biological contexts.
Other biological outcomes of the cross-talk between NF-kB and JNK/ROS signaling Of note, cross-talk between the NF-kB and JNK pathways may occur at multiple levels and may have, depending on the context, different biological outcomes (Zhang and Chen, 2004) . Firstly, in many signaling pathways, NF-kB, JNK and ROS share common upstream molecules, including kinases and adapter proteins such as IRAK, MEKKs and TAK, for their activation (Zhang and Chen, 2004; Gloire et al., 2006) . Secondly, whereas NF-kB is capable of inducing expression of molecules that trigger JNK activation such as TNFa, IL-1b and Fas ligand (Hayden and Ghosh, 2004; Zhang and Chen, 2004) , JNK can upregulate expression of factors involved in activation of NF-kB by various stimuli such as the E3-ubiquitin ligase, b-TrCP (Spiegelman et al., 2001) . Additionally, functional interaction between the NF-kB and JNK pathways can occur at the transcriptional level, as the promoters of several genes controlling inflammation, PCD and tumorigenesis are jointly regulated by NF-kB and JNK-controlled transcription factors such as AP1 (Lamb et al., 2003; Zhang and Chen, 2004; Karin and Gallagher, 2005) .
It is also worth noting that promotion of cell survival is unlikely to be the sole biological outcome of an interaction between NF-kB and JNK. Indeed, whereas being usually a signal for survival, NF-kB activity in certain circumstances can promote PCD (Kucharczak et al., 2003; Karin, 2006; Papa et al., 2006; Perkins and Gilmore, 2006; see Dutta et al., 2006) . This deathinducing role for NF-kB was reported, for instance, during oxidative injury in some systems (Luo et al., 1999; Vollgraf et al., 1999; Shou et al., 2000; Aoki et al., 2001) . The basis for participation of NF-kB in PCD signaling remains unclear, but several possible mechanisms have been proposed (Kucharczak et al., 2003; Perkins and Gilmore, 2006) . Likewise, in addition to induction of cell death, JNK has been implicated in cell growth, differentiation and even in cell survival in some systems. (Davis, 2000; Lamb et al., 2003; Karin and Gallagher, 2005) . This biological function of JNK appears to depend upon tissue-and context-specific elements (Davis, 2000) . Thus, in certain contexts, the death-inducing and antiproliferative effects of NF-kB might be owed in part to an interference with the JNK pathway. A clear illustration of this concept is offered by studies of the epidermal epithelium. Despite its wellcharacterized prooncogenic role in various tissues (Karin, 2006; Kim et al., 2006) , the NF-kB-mediated suppression of JNK signaling in epidermal keratinocytes was found to promote growth arrest, differentiation and tumor suppression -as proliferation and neoplastic outgrowth in this tissue are often reliant on JNK activity Karin, 2006) . Indeed, NF-kB might exert a similar function in tumor suppression in the liver (Karin, 2006 ) (see below).
In vivo relevance of the NF-jB-mediated control of ROS and JNK activities
Response of the liver to stress and injury The biological relevance of the negative regulation that NF-kB imposes on ROS and JNK signaling has been documented in animal models, most notably in the liver (Karin, 2006; Schwabe and Brenner, 2006) . Recent studies showed that NF-kB is required to antagonize hepato-toxicity caused by systemic administration of ConA, which provokes massive liver damage through a mechanism that requires TNF-Rs (Maeda et al., 2003) . Conditional knockout of ikkb in hepatocytes leads to sustained activation of JNK signaling following challenge with ConA, and inhibition of this signaling by ablation of either jnk1 or jnk2 markedly attenuates ConA-elicited injury in NF-kB-deficient livers (Maeda et al., 2003) . Consistent with recent findings on the mechanisms underlying JNK-mediated toxicity, Itch À/À mice are refractory to TNFa-induced liver failure in various models of hepatic challenge, and cells from either these or jnk1 À/À mice exhibit defective ubiquitinmediated proteolysis of c-FLIP L during these challenges (Chang et al., 2006; Schwabe and Brenner, 2006) . Thus, the NF-kB-mediated restraint of JNK activation plays a crucial role in preventing hepatic damage in vivo. A similar mechanism might mediate the protective action of NF-kB in the fetal liver (Beg et al., 1995 , Kucharczak et al., 2003 .
TNF-R1 and NF-kB also play important roles in the regenerative response of the liver following partial hepatectomy Schwabe and Brenner, 2006) . Of interest, NF-kB appears to exert its critical influence on this process, at least in part, also through a control of JNK signaling Schwabe and Brenner, 2006) . Notably, however, there is evidence that, whereas in the ConA model both sustained activation of the JNK cascade and hepatic damage are dependent upon ROS formation, in the partial hepatectomy model, neither JNK induction nor compensatory liver growth appears to require ROS (Kamata et al., 2005; Schwabe and Brenner, 2006) -despite both processes being dependent on an integration of TNF-Rs, NF-kB and JNK activities (Karin, 2006; Schwabe and Brenner, 2006) . Hence, in the same tissue (i.e., the hepatic tissue), during different biological responses, both the TNF-R-elicited pathways leading to JNK activation and the NF-kB-induced program that restrains this activation and hepatic damage are seemingly mediated through different mechanisms (see also below).
Chronic inflammatory and hereditary disorders
Disturbances in the NF-kB-imposed suppression of TNF-R-induced killing play a central role in the pathogenesis of a wide spectrum of human diseases (Kucharczak et al., 2003 , Kumar et al., 2004 Courtois and Smahi, 2006; Karin, 2006; Kim et al., 2006; Papa et al., 2006) . In some of these diseases, the pathogenetic action of NF-kB appears to involve a deregulation of ROS and JNK activities. This is especially evident in conditions such as IBD and RA, where inflammation is perpetuated by a mutual positive regulation of TNFa and NF-kB (Aggarwal, 2003; Kucharczak et al., 2003; Kumar et al., 2004) . Inhibitors of NF-kB, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, and antibodies neutralizing TNFa are routinely used to treat these conditions (Kucharczak et al., 2003; Greten and Karin, 2004; Karin et al., 2004; Kumar et al., 2004) . Further, an elevation of ROS and JNK activities are consistently found at sites of inflammation (Aggarwal, 2003; Victor et al., 2004; Karin, 2006) . This is owed in part to the oxidative burst that is associated with activation of immune and inflammatory cells, and usually involves an upregulation of arachidonic acid metabolism and NADPH oxidase activity (Haddad, 2002; Victor et al., 2004) . The relevance of the control that NF-kB exerts on ROS and JNK signaling is likely to extend to other conditions in which these activities may play a significant pathogenetic role, such as other inflammatory diseases, sepsis, ischemia/reperfusion injury, and cardiovascular and neuro-degenerative diseases, including Parkinson's and Alzheimer's diseases (Haddad, 2002; Kumar et al., 2004; Victor et al., 2004; Mattson and Meffert, 2006) . Finally, an NF-kB-dependent deregulation of the ROS/JNK pathway may contribute to the pathogenesis of certain hereditary disorders characterized by either impaired or exaggerated NF-kB activity and, consequently, an imbalance in cell survival (Courtois and Smahi, 2006; Papa et al., 2006) .
Cancer
Finally, the relevance of the cross-talk between NF-kB and ROS/JNK signaling might apply to cancer. In various tumors, JNK and NF-kB appear to have opposing biological effects. Inducers of the JNK cascade, such as the JNK kinase, MKK4, JNK3 and BRCA1, and JNK-controlled transcription factors, such as JunB and JunD, have been implicated in tumor suppression (Kennedy and Davis, 2003; Papa et al., 2006) . ROS and JNK can also mediate tumor cell killing inflicted by radiation and certain anticancer drugs (Benhar et al., 2002; Curtin et al., 2002; Martindale and Holbrook, 2002; Zhang and Chen, 2004) . Conversely, activation of NF-kB has been associated with promotion of cell viability during oncogenic transformation, survival of late-stage tumors (Gilmore, 2003) and resistance of cancer cells to anticancer therapy (Orlowski and Baldwin, 2002; Kucharczak et al., 2003; Greten and Karin, 2004; Kim et al., 2006) . Hence, because several oncogene products, such as Her-2/Neu and mutant Ras, as well as chemotherapeutic agents such as topoisomerase inhibitors, proteasome inhibitors and trivalent arsenicals, are potent elicitors of both ROS and JNK activities (Kennedy and Davis, 2003; Greten and Karin, 2004; Karin et al., 2004; Kim et al., 2006; Papa et al., 2006) , cancerous cells might require the prosurvival action of NF-kB in order to suppress ROSand/or JNK-mediated killing triggered by these oncogene products or anticancer agents. The discovery that the growth of certain primary and metastatic tumors relies on an NF-kB-driven inflammatory reaction engulfing the cancerous tissue (Pikarsky et al., 2004; Maeda et al., 2005; Karin, 2006) , may provide yet another link between cancer progression and the inhibitory activity of NF-kB on the ROS/JNK pathway. In fact, it is plausible that the requirement for NF-kB in growth and survival of inflammation-driven tumors is owed, at least in part, to a need to contain cytotoxic ROS and JNK signaling.
Therapeutic challenges and opportunities
The central role that NF-kB plays in human diseases, such as cardiovascular and chronic inflammatory diseases, is underscored by the widespread use of NF-kBtargeting agents (e.g., NSAIDs and glucocorticoids) for treatment of these diseases Kucharczak et al., 2003; Karin et al., 2004; Kumar et al., 2004; see De Bosscher et al., 2006) . Inhibitors of NF-kB, including proteasome inhibitors, are also being increasingly used in patients with certain malignancies such as multiple myeloma, Hodgkin's lymphoma (HL), non-HL and certain solid tumors (Kucharczak et al., 2003; Greten and Karin, 2004; Karin et al., 2004; Kim et al., 2006; Papa et al., 2006; see Gilmore and Herscovitch, 2006) . A major concern with prolonged blockade of NF-kB, howeveras in the case of chronic conditions -is the onset of severe side effects, including immunosuppressive effects (Kucharczak et al., 2003; Karin et al., 2004) . Most available blockers of NF-kB, including corticosteroids, NSAIDs and proteasome inhibitors, also lack specificity for the NF-kB pathway, which is cause for additional side effects (Greten and Karin, 2004; Karin et al., 2004; Kim et al., 2006) . Notably, even drugs that are potentially more specific for the NF-kB pathway, such as inhibitors of IKK -currently being tested in vitro and in preclinical trials -are likely to have serious adverse effects, even beyond those caused by immunosuppression. Indeed, studies in mice now show that, in certain organs, such as the liver and the skin, long-term suppression of NF-kB -even when achieved through highly specific means such as genetic means -can paradoxically promote carcinogenesis Maeda et al., 2005; Karin, 2006) .
A new approach to therapy is therefore needed. An important goal in this regard is to achieve selective inhibition of specific functions of NF-kB, such as prosurvival function, rather than of NF-kB itself. The discovery that the NF-kB-mediated antagonism of PCD involves a restraint of ROS and JNK signaling (Nakano et al., 2006; Papa et al., 2006) now offers an opportunity for achieving this goal. Indeed, therapeutic agents that selectively interfere with the restraint of this signaling by NF-kB are likely to enhance PCD preferentially in immune and inflammatory cells at sites of inflammation where there are high levels of TNFa and JNK and ROS activities (Kumar et al., 2004; Victor et al., 2004) . Such agents might also lead to elevation of cytotoxic ROS/ JNK signaling in cancerous cells, particularly in those requiring an inflammatory reaction for their growth, and so, provide a powerful new adjuvant for standard anticancer treatments (Karin, 2006; Papa et al., 2006) . Drugs that impede, for instance, Gadd45b binding to MKK7, FHC-mediated sequestration of iron or activity of MKPs might indeed succeed in producing these desirable outcomes.
Because the inhibitory action that NF-kB exerts on ROS and JNK activities is mediated through a specialized subset of target genes (Papa et al., 2006) , this therapeutic approach might also enable dissociation of prosurvival and immune functions of NF-kB, and thus, minimize side effects associated with standard NF-kB inhibitors, such as immunosuppressive effects (Kucharczak et al., 2003; Karin et al., 2004) . Indeed, because the NF-kB-activated program targeting the ROS/JNK pathway also exhibits a degree of cell-type and context specificity (Kucharczak et al., 2003; Papa et al., 2006) , it might even be possible to achieve selective inhibition of this program in diseased tissues. Recent studies investigating the function of NF-kB in the liver provide an exemplary illustration of this concept (Karin, 2006; Schwabe and Brenner, 2006) . It was shown that, in the liver, both the mechanisms by which TNF-Rs trigger activation of JNK and tissue injury and those underlying the protective action of NF-kB by means of blocking this activation differ depending upon whether stimulation of TNF-Rs occurs in the context of a challenge with ConA or in tissue regeneration following partial hepatectomy ; see also Karin, 2006; Schwabe and Brenner, 2006 ). Thus, a major future challenge includes determining the precise mechanisms through which NF-kB counters ROS accumulation and JNK signaling in specific pathophysiological contexts. Another important challenge, especially in anticancer therapy, is establishing which targets of NF-kB are most crucial for suppression of programmed necrosis, as it is becoming increasingly clear that cancerous cells are particularly prone to undergo this type of cell death (Edinger and Thompson, 2004; Hammerman et al., 2004) . In light of the roles that ROS and JNK activities play in necrosis, it is plausible that interference with the NF-kB-mediated suppression of these activities may enable the triggering of necrosis signaling in cancer cells.
Concluding remarks and future perspectives
Recent years have seen major advances in our understanding of the signal transduction pathways leading to NF-kB activation downstream of various receptors. In contrast, there has been relatively limited progress towards gaining an understanding of the molecular steps in these pathways that are under redox control. Delineating these steps will be key for establishing the relevance of ROS to activation of NF-kB. It might also help unveil the basis for the apparent tissue specificity of the effects of ROS on NF-kB activation. In light of the recent progress in delineating the molecular events involved in the NF-kB signaling pathways, now might be an appropriate time to revisit the evidence for the oxidative stress model of NF-kB activation. Another important challenge will be to determine the sources of ROS used to control NF-kB activity following exposure to stress and cytokines.
A major discovery in recent years has been the existence of a reciprocal, negative cross-talk between NF-kB and ROS. The restraint that NF-kB imposes on ROS (and JNK) signaling appears to be critical for the control of cell fate in both health and disease. Much progress has been recently made towards gaining an understanding of the basis for this restraint. The identification of NF-kB-inducible inhibitors of the ROS/JNK pathway has been an important step in this direction. Multiple such inhibitors have been characterized thus far, and this redundancy of factors might serve to ensure the effective shutdown of ROS and JNK signaling. It might also enable an organism to finely tune its prosurvival response according to specific contexts and needs. Undoubtedly, major future challenges include determining the precise mechanisms responsible for the mutual positive cross-talk between ROS and JNK activities in the induction of PCD, and establishing which NF-kB-inducible genes are most critical for control of these activities in specific pathophysiological contexts. Because inappropriate blockade of PCD by NF-kB appears to underlie various human diseases, these efforts might enable the development of new, highly effective therapies for treatment of these diseases. Because functions of NF-kB in immunity, development and cell survival are executed in part through distinct subsets of target genes, the possibility also exists for developing drugs that achieve selective blockade of the prosurvival action of NF-kB, without significantly harming the capacity of this factor to serve in immunity and development. This strategy could minimize many of the side effects of standard NF-kB blockers. Finally, because NF-kB, JNK and ROS activities are predominantly upregulated in inflamed and cancerous tissues, therapeutic strategies aimed at interfering with the antagonistic interplay between NFkB and the ROS/JNK pathway might have inherent specificity for diseased tissues. Achieving this specificity represents a major therapeutic goal.
